Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rat somatic genome editing enables ER+ breast cancer modeling.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Extracorporeal Albumin Dialysis (OPAL) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure.

Artificial organs·2026
Same author

NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis.

Cancer letters·2026
Same author

ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis through Symbiotic Adhesion and Reverse Migration.

Cancer research·2026
Same author

iS2C2: a cointelligent platform for mechanistic discovery of disease cellular crosstalk.

Signal transduction and targeted therapy·2026
Same author

Unbiased niche labeling maps immune-excluded niche in bone metastasis.

Cell·2026

Related Experiment Video

Updated: Mar 9, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Repurposing Antiestrogens for Tumor Immunotherapy.

Thomas Welte1, Xiang H-F Zhang1, Jeffrey M Rosen2

  • 1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.

Cancer Discovery
|January 8, 2017
PubMed
Summary
This summary is machine-generated.

Estrogen receptor alpha-positive cells in ovarian cancer stroma were identified as immunosuppressive myeloid-derived suppressor cells (MDSC). Targeting these MDSCs with antiestrogen therapy suggests combined endocrine and immunotherapy may benefit ovarian cancer patients.

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.2K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.3K

Related Experiment Videos

Last Updated: Mar 9, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.2K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.3K

Area of Science:

  • Oncology
  • Immunology
  • Endocrinology

Background:

  • Estrogen receptor alpha (ERα)-positive cells were observed in the tumor stroma of ovarian cancer patients.
  • These ERα-positive cells were independent of tumor ER status and type.

Purpose of the Study:

  • To identify the cell type responsible for ERα expression in the ovarian cancer stroma.
  • To investigate the therapeutic potential of targeting these cells in ovarian cancer.

Main Methods:

  • Immunohistochemistry to identify ERα-positive cells in tumor stroma.
  • Flow cytometry and functional assays to characterize the identified cells.
  • In vitro and in vivo models to assess therapeutic responses.

Main Results:

  • The observed ERα-positive stromal cells were identified as myeloid-derived suppressor cells (MDSCs).
  • These MDSCs exhibited immunosuppressive functions.
  • Antiestrogen therapy demonstrated the ability to target and potentially reduce these immunosuppressive MDSCs.

Conclusions:

  • Myeloid-derived suppressor cells expressing estrogen receptor alpha are present in the ovarian cancer stroma.
  • Targeting these MDSCs with antiestrogen therapy offers a novel therapeutic strategy.
  • Combination therapy with endocrine agents and immunotherapy may enhance treatment efficacy by reducing MDSC-mediated immunosuppression in ovarian cancer.